What are Macrophage-Directed Bioassays?
Macrophage-directed therapies have emerged as a promising avenue in the field of immunotherapy, harnessing the unique biology of macrophages to eliminate pathogens and cancer cells. These therapies focus on enhancing macrophage functions, such as antibody-dependent cellular phagocytosis (ADCP) mediated by Fcγ receptors, to improve the clearance of targeted cells. Additionally, the manipulation of macrophage-associated receptors, including Toll-like receptors (TLRs) and the immune checkpoints SIRPα/CD47 and ILT4(LILRB2), holds great potential for modulating macrophage activation. By exploiting the multifaceted nature of macrophages, these targeted approaches aim to revolutionize the treatment of various diseases, from infectious disease to cancer.
Biologic therapeutics are in clinical trials to test these mechanisms of action as a promising strategy for cancer immunotherapy. Cell-based reporter bioassays are critical tools to quantify the activity of these molecules for ranking, potency and stability purposes.